Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Evaluating a New Sensor That Measures the Health of the Retina in Normally-sighted Subjects

NCT: NCT05509608 · ACTIVE_NOT_RECRUITING

NCT IDNCT05509608
StatusACTIVE_NOT_RECRUITING
Start Date2023-03-01
Completion2026-12-31
SponsorRetMap, Inc (INDUSTRY)
First posted
Last updated

Brief Summary

The primary purpose of this study is to evaluate the ability of a new contact lens electrode to record a measurable electroretinogram (ERG). ERG sensors in various forms have been in common clinical use for more than 50 years. The ERG sensor that is the subject of this study is the RM Electrode, developed by RetMap, Inc. (project sponsor). The RM Electrode is not yet approved by the FDA. The RM Electrode will be compared to other commercially available electrode The first Aim of the present study is to compare the functionality of the RM Electrode and other commercially available electrodes. Following standard ERG test protocols, responses will be recorded from ten healthy (normally-sighted) adult subjects using both electrodes (used in random order). The signal quality of the ERG responses obtained from both contact lens electrodes will be compared. Signal quality will be determined by measuring ERG signal amplitudes and calculating signal-to-noise ratios (SNR). Signal-to-noise ratios will be used to establish substantial equivalence. ERG test results will not be used to determine the effect of the devices on the participants. The second Aim of the present study is to evaluate the risk of ocular irritation caused by use of the RM Electrode compared to other commercially available electrodes. A typical ERG test session lasts 20 minutes. Ten healthy (normally-sighted) adult subjects will wear the RM Electrode on one eye and a commercially available electrode on the other eye, for a total of 60 minutes, in 20-minute sessions with short breaks in between. To determine the effect of the devices on the participants, the eyes will be evaluated for irritation.

Frequently Asked Questions

What is Evaluating a New Sensor That Measures the Health of the Retina in Normally-sighted Subjects?

Evaluating a New Sensor That Measures the Health of the Retina in Normally-sighted Subjects is a clinical trial registered under NCT05509608. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT05509608?

The current status of NCT05509608 (Evaluating a New Sensor That Measures the Health of the Retina in Normally-sighted Subjects) is: ACTIVE_NOT_RECRUITING.

When did Evaluating a New Sensor That Measures the Health of the Retina in Normally-sighted Subjects start?

Evaluating a New Sensor That Measures the Health of the Retina in Normally-sighted Subjects started on 2023-03-01.

Related Devices

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.